H
Houssem Benlalam
Researcher at French Institute of Health and Medical Research
Publications - 18
Citations - 693
Houssem Benlalam is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 11, co-authored 17 publications receiving 634 citations. Previous affiliations of Houssem Benlalam include University of Nantes & Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells.
Salem Chouaib,Claudine Kieda,Houssem Benlalam,Muhammad Zaeem Noman,Fathia Mami-Chouaib,Curzio Rüegg +5 more
TL;DR: The role played by circulating endothelial progenitor cells is addressed and their features and mechanism of recruitment to the tumor microenvironment and their role in tumor angiogenesis are illustrated.
Journal ArticleDOI
A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion
Boris Linard,Stéphane Bézieau,Houssem Benlalam,Nathalie Labarrière,Yannick Guilloux,Elisabeth Diez,Francine Jotereau +6 more
TL;DR: Data show that oncogenic protein mutations can create shared tumor-specific CTL epitopes, efficiently presented by tumor cells, and that screening for oncogene-transfected COS cell recognition by TIL (from tumors containing mutations) is a powerful approach for the identification of these epitopes.
Journal ArticleDOI
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
Houssem Benlalam,Nathalie Labarrière,Boris Linard,Laurent Derré,Elisabeth Diez,Marie-Christine Pandolfino,Marc Bonneville,Francine Jotereau +7 more
TL;DR: This study, which is to the authors' knowledge the most comprehensive analysis of TIL specificity to tumor antigens, has several implications for the design of immunotherapeutic strategies based on immunization against selected tumor epitopes.
Journal ArticleDOI
ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway
Ahmed Hamaï,Franck Meslin,Houssem Benlalam,Abdelali Jalil,Maryam Mehrpour,Florence Faure,Yann Lécluse,Philipe Vielh,Marie-Françoise Avril,Caroline Robert,Salem Chouaib +10 more
TL;DR: The present study shows that a shift in ICAM-1 expression, which was associated with an activation of the PI3K/AKT pathway, can be used by metastatic melanoma cells to escape CTL-mediated killing.
Journal ArticleDOI
Immune surveillance of human cancer: If the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
A. Hamaï,Houssem Benlalam,Franck Meslin,Meriem Hasmim,Thibault Carré,Intissar Akalay,Bassam Janji,Guy Berchem,Muhammad Zaeem Noman,Salem Chouaib +9 more
TL;DR: New mechanisms associated with the acquisition of tumor resistance to specific lysis during tumor progression, involving genetic instability, structural changes in cytoskeleton, and hypoxic stress are focused on.